ING Groep NV grew its position in Hill-Rom Holdings, Inc. (NYSE:HRC) by 40.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,153 shares of the medical technology company’s stock after purchasing an additional 1,187 shares during the quarter. ING Groep NV’s holdings in Hill-Rom were worth $363,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of HRC. Bank of Montreal Can bought a new stake in shares of Hill-Rom in the 2nd quarter valued at $148,571,000. Ceredex Value Advisors LLC bought a new position in Hill-Rom during the first quarter worth $92,503,000. BlackRock Inc. boosted its stake in Hill-Rom by 8.7% during the first quarter. BlackRock Inc. now owns 6,176,659 shares of the medical technology company’s stock worth $537,367,000 after acquiring an additional 496,435 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its stake in Hill-Rom by 10,137.2% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 392,289 shares of the medical technology company’s stock worth $34,128,000 after acquiring an additional 388,457 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its stake in Hill-Rom by 29.2% during the first quarter. Lord Abbett & CO. LLC now owns 1,166,497 shares of the medical technology company’s stock worth $101,485,000 after acquiring an additional 263,612 shares in the last quarter. 84.91% of the stock is currently owned by institutional investors.
In other Hill-Rom news, SVP Alton Shader sold 16,812 shares of the firm’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $93.70, for a total value of $1,575,284.40. Following the transaction, the senior vice president now directly owns 54,898 shares of the company’s stock, valued at $5,143,942.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is currently owned by company insiders.
Several brokerages recently issued reports on HRC. KeyCorp increased their target price on shares of Hill-Rom from $97.00 to $115.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 17th. Raymond James increased their target price on shares of Hill-Rom from $97.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, July 30th. Zacks Investment Research raised shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a research note on Monday, July 2nd. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Saturday, June 16th. Finally, Northcoast Research reissued a “buy” rating and set a $104.00 target price on shares of Hill-Rom in a research note on Tuesday, July 31st. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $100.00.
Shares of NYSE HRC opened at $94.98 on Friday. The firm has a market cap of $6.33 billion, a P/E ratio of 24.61, a P/E/G ratio of 1.48 and a beta of 0.89. Hill-Rom Holdings, Inc. has a 12-month low of $71.91 and a 12-month high of $98.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.18 and a current ratio of 1.58.
Hill-Rom (NYSE:HRC) last released its quarterly earnings data on Friday, July 27th. The medical technology company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.02. Hill-Rom had a net margin of 8.19% and a return on equity of 20.54%. The firm had revenue of $708.60 million for the quarter, compared to analyst estimates of $707.50 million. During the same period last year, the firm earned $0.91 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. equities research analysts predict that Hill-Rom Holdings, Inc. will post 4.64 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Shareholders of record on Friday, September 21st will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Thursday, September 20th. Hill-Rom’s dividend payout ratio (DPR) is 20.73%.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Story: What are CEFs?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.